copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
Diagnosis and Treatment of ALK Positive NSCLC - PMC Pharmacologic Treatment Options Crizotinib Crizotinib is a potent, orally available, ATP-competitive, small-molecule inhibitor of ALK and Met receptor tyrosine kinases that entered initial clinical trials in 2006 prior to the discovery of ALK rearrangements in NSCLC
ALK+ NSCLC Treatment Guidelines Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . . The molecular pathogenesis, clinical features, and treatment of NSCLC associated with the ALK fusion oncogene are discussed here An overview of the treatment of metastatic NSCLC, ALK-positive early NSCLC, and the methods and indications for molecular testing are presented elsewhere
Real-world treatment sequencing and effectiveness of second . . . With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
Evaluating Diagnostic and Treatment Timelines for ALK . . . MicroabstractThe ALK Life Study analyzed diagnostic and treatment timelines in 1288 ALK-positive NSCLC patients from 71 countries The median time to diagnosis was 45 days, and time to TKI treatment was 30 days for advanced-stage patients Younger age, comorbidities, and geographic factors were linked to delays Outcomes may be improved by raising awareness amongst clinicians of the frequency
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A . . . Notably, the longest OS was observed in patients treated with crizotinib who received ALK inhibitors in subsequent treatment The aforementioned ASCEND-4 study was a randomized, phase III study that compared the second-generation ALK inhibitor, ceritinib, with chemotherapy as first-line treatment for patients with advanced ALK -rearranged NSCLC 3
Targeting ALK Rearrangements in NSCLC: Current State of the Art Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC